Isabl
Founded 2020 · 8 employees on LinkedIn · 4 known investors
Isabl develops genomic sequencing technology for cancer diagnosis, enabling whole genome and transcriptome testing in clinically relevant timeframes to provide comprehensive treatment options. The platform serves physicians and cancer patients globally by making advanced molecular diagnostics accessible.
Also known as Isabl Inc.
Investors · 4
Company profile
researched Aug 2026Isabl Inc. is a cancer genomics company that analyzes the entire tumor genome and transcriptome rather than relying on targeted gene panels. Its stated aim is to identify cancer-associated mutations in every sample analyzed and to broaden biomarker discovery for patients who do not benefit from existing panel-based diagnostic tests. The core offering is described as GxT technology, presented by the company as a comprehensive genomic test in cancer covering complete analysis of the tumor genome and transcriptome, and delivered commercially as a whole genome and transcriptome sequencing (WGTS) software-as-a-service.
The company was established in 2020 as a spin-off from Memorial Sloan Kettering Cancer Center. Its team is described as combining specialists in cancer genomics, molecular diagnostics, oncology and biomarker development drawn from institutions including Memorial Sloan Kettering, Harvard and Weill Cornell Medicine. Isabl states it has received FDA Breakthrough Device Designation for its GxT technology.
Founding story
Isabl Inc. was created in 2020 as a spin-off from Memorial Sloan Kettering Cancer Center.
Business model
Isabl markets its whole genome and transcriptome sequencing analysis as a software-as-a-service (WGTS SaaS) offering, with prospective customers invited to schedule meetings with the company.
▸Full profile — market position, technology, go-to-market, history
Market position
Isabl operates in tumor genomic profiling, offering comprehensive whole genome and transcriptome testing as an alternative to established panel-based cancer diagnostics.
The company positions its complete tumor genome and transcriptome analysis against panel-based genomic tests, arguing that full analysis identifies relevant mutations in every sample and expands biomarker discovery to patients not served by panel testing.
Technology
Isabl's GxT technology analyzes 100% of the tumor genome and transcriptome, in contrast to panel-based diagnostic tests that assess a limited set of genes, with the goal of revealing relevant cancer-associated mutations in every sample and supporting broader biomarker discovery.
Go-to-market
Direct engagement through the company website, where prospective customers are invited to schedule meetings to learn about the WGTS SaaS offering.
Oncology and molecular diagnostics stakeholders involved in tumor genomic profiling, addressing cancer patients whose tumors are not adequately characterized by panel-based tests.
History
Founded in 2020 as a Memorial Sloan Kettering Cancer Center spin-off, Isabl has been funded by Two Sigma Ventures, Y Combinator, BoxOne Ventures and other investors, and reports receiving FDA Breakthrough Device Designation for its GxT technology.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsIsabl Inc. was founded as a spin-off from Memorial Sloan Kettering Cancer Center in 2020.
The company states it is a recipient of the FDA Breakthrough Device Designation for its GxT whole genome and transcriptome sequencing technology.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- Isablisabl.info · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Isabl do?
- Isabl is a cancer genomics company offering whole genome and transcriptome sequencing analysis for tumor profiling.
- Who are Isabl's investors?
- Isabl's investors include BoxOne Ventures, Two Sigma Ventures, Y Combinator, Evolution VC Partners.